GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan
January 30, 2025 02:40 ET | Source: GENFIT S.A.
Share
GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital:
€130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestones
Closing subject to approval by the 2025 OCEANE bondholders at upcoming bondholders meeting
Financing would extend cash runway beyond the end of 2027, assuming drawdown of all instalments
Proceeds to further strengthen the development of the ACLF pipeline
In return, HCRx will receive a portion of royalties on global1 sales of Iqirvo® (elafibranor) payable to GENFIT under its licensing agreement with Ipsen, up to an agreed upon cap after which all future royalties will revert back to GENFIT
GENFIT retains rights to all future regulatory, commercial and sales-based milestone payments from Ipsen under the Ipsen agreement
GENFIT to concurrently propose a repurchase of the 2025 OCEANEs aiming to completely eliminate GENFIT’s convertible debt overhang
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 30, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces that it has entered into a non-dilutive capped royalty financing agreement with HealthCare Royalty (HCRx) for up to €185 million, and debt overhang resolution plan.
Pascal Prigent, CEO of GENFIT, commented: “This non-dilutive financial agreement is a pivotal step in strengthening our financial outlook, extending our cash runway beyond 2027. We are also proposing to repurchase the outstanding 2025 OCEANE bonds to eliminate our convertible debt overhang. This financing transaction will position GENFIT to operate on strong foundations to deliver on its R&D pipeline objectives in ACLF.”
Clarke Futch, Chairman and Chief Executive Officer of HCRx, added: “With this investment, HCRx underscores its commitment to supporting innovative biopharmaceutical companies that create long-term value. We firmly believe in the strong potential that Iqirvo® delivers to patients with high unmet medical need, and are excited to collaborate with GENFIT on this transaction.”
Highlights
Corporate context
In December 2021, GENFIT entered into a long-term strategic partnership with Ipsen (the “Ipsen agreement”). The agreement grants Ipsen an exclusive worldwide license (excluding China, Hong Kong, Taiwan and Macau for which Terns Pharmaceuticals has a prior license) to develop, manufacture, and commercialize elafibranor for people living with Primary Biliary Cholangitis (PBC), and in other indications. Under the terms of the Ipsen agreement, GENFIT is eligible for regulatory, commercial, and sales-based milestone payments and royalties, based on product sales.
In 2024, Iqirvo® (elafibranor) received accelerated approval from the U.S. Federal Drug Administration for sale in the United States and conditional